Highlights of mechanistic and therapeutic Cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology

Archives of Medical Science

Volumn 9, Issue 1, 2013, Pages 166-171

  Anker, Markus S ^a   Von Haehling, Stephan ^b   Springer, Jochen ^c   Banach, MacIej ^d   Anker, Stefan D ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cachexia; Cardiovascular illness; Heart failure; Mechanism; Muscle wasting; Sarcopenia; Therapy

Indexed keywords

ANABOLIC AGENT; ANAMORELIN; BL 6020; ENOBOSARM; HEAT SHOCK PROTEIN 72; HORMONE RECEPTOR BLOCKING AGENT; ICOSAPENTAENOIC ACID; IMIDAPRIL; MT 102; MYOSTATIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CACHEXIA; HEART FAILURE; HUMAN; INSULIN RESISTANCE; MEDICAL RESEARCH; METABOLIC SYNDROME X; MUSCLE ATROPHY;

EID: 84874820388     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.33356     Document Type: Article

References (105)

1. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-63.
2. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-96.
3. Janssen I. Influence of sarcopenia on the development of physical disability: the cardiovascular health study. J Am Geriatr Soc 2006; 54: 56-62.
4. Rolland Y, Lauwers-Cances V, Cournot M, et al. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. J Am Geriatr Soc 2003; 51: 1120-4.
5. Lauretani F, Russo CR, Bandinelli S, et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003; 95: 1851-60.
6. Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care 1999; 8: 133-6.
7. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-7.
8. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008; 12: 1193-201.
9. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-3.
10. Mak RH, Cheung W. Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol 2006; 21: 1807-14.
11. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M. Anorexia in chronic obstructive pulmonary disease - association to cachexia and hormonal derangement. Int J Cardiol 2007; 119: 83-9.
12. Vermeeren MA, Creutzberg EC, Schols AM, Postma DS, Pieters WR, Roldaan AC. COSMIC Study group. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006; 100: 1349-55.
13. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The national institutes of health intermittent positivepressure breathing trial. Am Rev Respir Dis 1989; 139: 1435-8.
14. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-6.
15. Elkan AC, Ha°kansson N, Frostega°rd J, Cederholm T, Hafström I. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009; 11: R37.
16. Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505-10.
17. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010; 1: 129-33.
18. von Haehling S, Anker SD. Cachexia as a major under - estimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010; 1: 1-5.
19. Scherbakov N, Doehner W. Sarcopenia in stroke - facts and numbers on muscle loss accounting for disability after stroke. J Cachexia Sarcopenia Muscle 2011; 2: 5-8.
20. Scott D, Blizzard L, Fell J, Jones G. The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? J Cachexia Sarcopenia Muscle 2011; 2: 125-34.
21. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011; 62: 265-79.
22. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009; 121: 227-52.
23. Remels AH, Gosker HR, Langen RC, Schols AM. The me - chanisms of cachexia underlying muscle dys function in COPD. J Appl Physiol 2012; DOI: 10.1152/japplphysiol. 00790.2012.
24. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010; 1: 9-21.
25. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother 2010; 11: 2575-8.
26. Kilgour RD, Vigano A, Trutschnigg B, et al. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2010; 1: 177-85.
27. Braun TP, Marks DL. Pathophysiology and treatment of inflammatory anorexia in chronic disease. J Cachexia Sarcopenia Muscle 2010; 1: 135-45.
28. Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle 2011; 2: 27-35.
29. Dioguardi FS. Clinical use of amino acids as dietary supplement: pros and cons. J Cachexia Sarcopenia Muscle 2011; 2: 75-80.
30. Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachexia Sarcopenia Muscle 2010; 1: 169-76.
31. Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. l-Carnitine and cancer cachexia: clinical and experimental aspects. J Cachexia Sarcopenia Muscle 2011; 2: 37-44.
32. Dallmann R, Weyermann P, Anklin C, et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 163-74.
33. Trobec K, von Haehling S, Anker SD, Lainscak M. Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 191-200.
34. Schefold JC, Bierbrauer J, Weber-Carstens S. Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Muscle 2010; 1: 147-57.
35. Lainscak M, von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011; 2: 81-6.
36. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur Heart J 2012 (in press).
37. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011; 2: 9-25.
38. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Iaina- Levin N, Kobus G, Dobrzycki S. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci 2011; 7: 658-64.
39. Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011; 7: 1055-66.
40. Cicoira M, Anker SD, Ronco C. Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle 2011; 2: 135-42.
41. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A. The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci 2010; 6: 539-44.
42. Couser WG, Riella MC. World Kidney Day 2011. Protect your kidneys, save your heart. Arch Med Sci 2011; 7: 1-4.
43. Kung T, Szabó T, Springer J, Doehner W, Anker SD, von Haehling S. Cachexia in heart disease: highlights from the ESC 2010. J Cachexia Sarcopenia Muscle 2011; 2: 63-9.
44. von Haehling S, Lainscak M, Doehner W, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle 2010; 1: 187-94.
45. Uematsu M, Akashi YJ, Ashikaga K, et al. Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation - a pilot study. Arch Med Sci 2012; 8: 622-30.
46. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011; 2: 143-51.
47. Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 2012; 125: 2716-27.
48. Sullivan-Gunn MJ, Campbell-O'Sullivan SP, Tisdale MJ, Lewandowski PA. Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle 2011; 2: 181-8.
49. Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle 2012; 3: 31-6.
50. von Haehling S, Schefold JC, Jankowska EA, et al. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol 2012; 59: 585-92.
51. Ulubay G, Ulasli SS, Bozbas SS, Ozdemirel T, Karatas M. Effects of peripheral neuropathy on exercise capacity and quality of life in patients with chronic obstructive pulmonary diseases. Arch Med Sci 2012; 8: 296-302.
52. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-34.
53. Jankowska EA, Filippatos G, Ponikowska B, et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 2009; 15: 442-50.
54. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114: 1829-37.
55. Toledo M, Busquets S, Ametller E, López-Soriano FJ, Argilés JM. Sirtuin 1 in skeletal muscle of cachectic tumourbearing rats: a role in impaired regeneration? J Cachexia Sarcopenia Muscle 2011; 2: 57-62.
56. Russ DW, Grandy JS. Increased desmin expression in hindlimb muscles of aging rats. J Cachexia Sarcopenia Muscle 2011; 2: 175-80.
57. Siren PM, Siren MJ. Systemic zinc redistribution and dyshomeostasis in cancer cachexia. J Cachexia Sarcopenia Muscle 2010; 1: 23-33.
58. Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci 2011; 7: 8-20.
59. Abbatecola AM, Paolisso G, Fattoretti P, et al. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging 2011; 15: 890-5.
60. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Ba - nach M. Metabolic syndrome and renal disease. Int J Cardiol 2012 (in press).
61. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term mul ti - factorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
62. Gehrig SM, van der Poel C, Sayer TA, et al. Hsp72 pre - serves muscle function and slows progression of severe muscular dystrophy. Nature 2012; 484: 394-8.
63. Gilbert PM, Havenstrite KL, Magnusson KE, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010; 329: 1078-81.
64. Sacco A, Mourkioti F, Tran R, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 2010; 143: 1059-71.
65. Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle 2011; 2: 111-7.
66. Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011; 333: 233-8.
67. Arner P. Medicine. Lipases in cachexia. Science 2011; 333: 163-4.
68. Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med 2011; 365: 565-7.
69. Pajak B, Orzechowska S, Pijet B, et al. Crossroads of cytokine signaling: the chase to stop muscle cachexia. J Physiol Pharmacol 2008; 59 (Suppl 9): 251-64.
70. Chen F, Lam R, Shaywitz D, et al. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle 2011; 2: 45-56.
71. Gluba A, Bielecka A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30: 1681-9.
72. Patel SS, Molnar MZ, Tayek JA, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle 2012 in press, DOI: 10.1007/s13539-012-0079-1.
73. Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol 2012 in press, DOI: 10.1016/j.exger.2012.03.002.
74. Cesari M, Fielding RA, Pahor M, et al.; International Working Group on Sarcopenia. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle 2012; 3: 181-90.
75. Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 105-9.
76. Müller TD, Perez-Tilve D, Tong J, Pfluger PT, Tschöp MH. Ghrelin and its potential in the treatment of eating/ wasting disorders and cachexia. J Cachexia Sarcopenia Muscle 2010; 1: 159-67.
77. Stepien M, Rosniak-Bak K, Paradowski M, et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med Sci Monit 2011; 17: PR13-8.
78. Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17betahydroxyestra- 4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 2010; 75: 377-89.
79. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-43.
80. Peter JC, Rossez H, Weckering M, et al. Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats. J Cachexia Sarcopenia Muscle 2012 [Epub ahead of print], PMID: 22911214.
81. von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol 2010; 144: 347-9.
82. Scarlett JM, Bowe DD, Zhu X, Batra AK, Grant WF, Marks DL. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J Endocrinol 2010; 206: 121-30.
83. Malkin CJ, Channer KS, Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2010; 17: 262-8.
84. Thum T, Springer J. Breakthrough in cachexia treatment through a novel selective androgen receptor modulator? J Cachexia Sarcopenia Muscle 2011; 2: 121-3.
85. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011; 2: 153-61.
86. http://www.clinicaltrials.gov - NCT01355497 & NCT01355484.
87. http://www.clinicaltrials.gov - NCT01387269 & NCT01387282.
88. Stewart Coats AJ, Srinivasan V, Surendran J, et al.; the ACT-ONE Trial Investigators. The ACT-ONE trial, a mul - ticentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transform - ing agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2011; 2: 201-7.
89. Schanze N, Springer J. Evidence for an effect of ACE in - hibitors on cancer cachexia. J Cachexia Sarcopenia Muscle 2012; 3: 139.
90. Penna F, Busquets S, Pin F, et al. Combined approach to counteract experimental cancer cachexia: eicosa pen - taenoic acid and training exercise. J Cachexia Sarcopenia Muscle 2011; 2: 95-104.
91. von Haehling S. The muscle in dire straits: mechanisms of wasting in heart failure. Circulation 2012; 125: 2686-8.
92. Macci A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: eva - luating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012; 124: 417-25.
93. Madeddu C, Dessí M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancerrelated anorexia/cachexia syndrome. Clin Nutr 2012; 31: 176-82.
94. Rozentryt P, von Haehling S, Lainscak M, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 2010; 1: 35-42.
95. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-9.
96. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current con - sensus definition: prevalence, etiology, and conse - quences. International working group on sarco penia. J Am Med Dir Assoc 2011; 12: 249-56.
97. Morley JE, Abbatecola AM, Argiles JM, et al.; Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011; 12: 403-9.
98. Argilés JM, López-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2011; 2: 87-93.
99. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010; 29: 154-9.
100. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-95.
101. Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011; 2: 1-3.
102. Baracos VE. Pitfalls in defining and quantifying cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 71-3.
103. Alagiakrishnan K, Banach M, Jones LG, Datta S, Ah med A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med 2012 in press, DOI: 10.3109/ 07853890. 2012.660493.
104. Karasek D, Sinkiewicz W, Błazejewski J. Relationship between B-type natriuretic peptide serum level, echo - cardiographic TEI index and the degree of diastolic dys - function in patients with heart failure with preserved systolic function. Arch Med Sci 2011; 7: 449-56.
105. von Haehling S, Anker SD. The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area. J Cachexia Sarcopenia Muscle 2011; 2: 189-90.